AMBEY — Ambey Laboratories Income Statement
0.000.00%
- IN₹945.48m
- IN₹1.08bn
- IN₹1.05bn
Annual income statement for Ambey Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
Standards: | IAS | IAS | IAS |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 817 | 846 | 1,048 |
Cost of Revenue | |||
Gross Profit | 154 | 157 | 149 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Depreciation and Amortization | |||
Unusual Expense / Income | |||
Other Operating Expenses | |||
Total Operating Expenses | 752 | 772 | 993 |
Operating Profit | 65.2 | 73.8 | 55.2 |
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | 30.9 | 48.3 | 62.2 |
Provision for Income Taxes | |||
Net Income After Taxes | 103 | 35.7 | 45.7 |
Net Income Before Extraordinary Items | |||
Net Income | 103 | 35.7 | 45.7 |
Adjustments to Net Income | |||
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | 103 | 35.7 | 45.7 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | 4.14 | 1.43 | 1.83 |